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Abstract
Age-related cognitive decline and many dementias involve complex interactions of both genetic and environ-
mental risk factors. Recent evidence has demonstrated a strong association of obesity with the development
of dementia. Furthermore, white matter damage is found in obese subjects and mouse models of obesity.
Here, we found that components of the complement cascade, including complement component 1qa (C1QA)
and C3 are increased in the brain of Western diet (WD)-fed obese mice, particularly in white matter regions.
To functionally test the role of the complement cascade in obesity-induced brain pathology, female and male
mice deficient in C1QA, an essential molecule in the activation of the classical pathway of the complement
cascade, were fed a WD and compared with WD-fed wild type (WT) mice, and to C1qa knock-out (KO) and
WT mice fed a control diet (CD). C1qa KO mice fed a WD became obese but did not show pericyte loss or a
decrease in laminin density in the cortex and hippocampus that was observed in obese WT controls.
Furthermore, obesity-induced microglia phagocytosis and breakdown of myelin in the corpus callosum were
also prevented by deficiency of C1QA. Collectively, these data show that C1QA is necessary for damage to
the cerebrovasculature and white matter damage in diet-induced obesity.
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Significance Statement
Economic growth, an increasingly sedentary lifestyle and a nutritional transition to processed foods and
high calorie diets have led to a significant increase in obesity prevalence. Several chronic diseases have
been associated with obesity, including dementia. Obesity-induced, peripheral inflammation has been pro-
posed as a possible trigger of pathologic changes in the brain that lead to cognitive dysfunction and predis-
position to dementia. Here we show that genetic deletion of the complement component 1qa (C1QA)
prevents cerebrovascular damage, neuroinflammation and white matter degradation in a mouse model of
Western diet (WD)-induced obesity, demonstrating that inflammatory responses play a significant role in
obesity-induced brain pathology. The complement pathway is an attractive therapeutic target to prevent
cognitive decline and reduction of dementia risk caused by obesity.
Introduction
Over the last 30 years, obesity prevalence has signifi-
cantly increased in many countries to the point that one
third of the world population is overweight or obese
(Hruby and Hu, 2015). In fact, it is projected that in the
United States, over 85% of adults will be overweight or
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obese by 2030 (Wang et al., 2008; Hruby and Hu, 2015).
Obesity has been defined as an excess of body weight for
height (body mass index .29). However, because of its
metabolic alterations and increased risk for the develop-
ment of chronic diseases, obesity is now considered an
energy metabolism disorder (Hruby and Hu, 2015).
Moreover, obesity has also been associated with the de-
velopment of mental disorders, cognitive dysfunction,
and dementia (Elias et al., 2005; Viscogliosi et al., 2013;
Singh-Manoux et al., 2018). Little is known about how
obesity promotes pathologic changes in the brain that are
not necessarily associated to chronic conditions such as
metabolic syndrome and type 2 diabetes. Nonetheless,
obesity-induced inflammation has been identified as a
possible trigger of pathologic changes in the brain that
lead to cognitive dysfunction and predisposition to neurode-
generative diseases like multiple sclerosis and Alzheimer’s
disease (AD; Miller and Spencer, 2014).
Previous studies in our laboratory have shown that
Western diet (WD)-induced obesity amplifies neuroinflam-
mation in the cortex and hippocampus of aged mice and
in a mouse model of AD (Graham et al., 2016, 2019). More
recently, we found significant infiltration of peripheral my-
eloid cells and neutrophils in the brain of diet-induced
obese mice, particularly in the cortex, the hippocampus
and the corpus callosum (Yang et al., 2019). These strong
neuroinflammatory responses are accompanied by be-
havioral deficits, neurovascular decline and increased deg-
radation of myelin by resident microglia or peripherally-
derived myeloid cells, despite the increased expression of
myelin proteins by oligodendrocytes (Graham et al., 2016,
2019). Importantly, white matter integrity throughout the
corpus callosum and frontal white matter is reduced in
cognitively normal older adults, patients with mild cognitive
impairment (MCI) and AD patients who are obese (Graham
et al., 2019), suggesting that white matter damage is a
pathologic hallmark of obesity.
It can be presumed that the chronic low-grade inflamma-
tory state in obesity influences the neurovascular decline
and the activation of microglia observed in the brain leading
to subsequent phagocytosis of myelin, but this has not
been critically tested. Furthermore, in vitro studies have
shown that myelin opsonization with complement compo-
nents and the presence of the complement receptor CR3
by microglia are required for maximal phagocytosis of mye-
lin, suggesting an important role of the complement path-
way in myelin phagocytosis (DeJong and Smith, 1997). It
has been shown that in multiple sclerosis lesions comple-
ment components colocalize with areas of active myelin
degradation along with the increased density of microglia/
macrophages expressing complement receptors (Barnett
et al., 2009; Grajchen et al., 2018; Loveless et al., 2018).
Although it is known that several components of the classi-
cal complement pathway are produced by adipose and pe-
ripheral immune cells in obese mice (Zhang et al., 2007),
evidence of activation of the complement pathway in the
brain during obesity is lacking. Here, we hypothesized that
myelin phagocytosis by microglia (or peripherally-derived
myeloid cells) in WD-induced obese mice was mediated by
the activation of the classical complement pathway. We
found that genetic deletion of C1qa did not change the
body composition or common blood-based markers of
metabolic syndrome in the WD-induced obese mice.
However, C1QA deficiency did significantly lessen cerebro-
vascular damage and the activation and phagocytic activity
of microglia in the cortex, hippocampus and corpus callos-
um preventing the degradation of myelin.
Materials and Methods
Animals
All methods are in accordance with The Jackson
Laboratory Institutional Animal Care and Use Committee
(IACUC) approved protocols. C57BL/6J (B6) mice (JAX
stock #000664), B6.C1qatm1a(EUCOMM)Wtsi/J, and B6.
C3tm1Crr/J (JAX stock #003641) mice were used in this
study and maintained in the Howell Laboratory colony.
B6.C1qatm1a(EUCOMM)Wtsi/J mice were created by back-
crossing B6N.C1qatm1a(EUCOMM)Wtsi/J mice at least 10
generations to C57BL/6J. Males were initially used exclu-
sively in this study to avoid effects of the estrus cycle, but
a second cohort of male and female mice were used to
determine possible sex differences in response to both
diet and complement deficiency. All mice were main-
tained on a 12/12 h light/dark cycle. Cohorts were main-
tained from wean on standard LabDiet 5K52 [referred to
as control diet (CD)]. Half of the cohorts were switched to
TestDiet 5W80 (referred to as WD; Graham et al., 2016).
Metabolic profiling
Glucose tolerance test (GTT) and insulin tolerance test (ITT)
GTT and ITT were performed in 12-month mice, following
10 months on the WD. After fasting for 5 h, GTT was per-
formed (Agri Laboratories, LTD) by intraperitoneal injection
of glucose (1g/kg, in saline). For the ITT, mice received a sin-
gle intraperitoneal injection of a diluted insulin solution
(males 0.75 IU/kg and females 0.50 IU/kg; prepared in sterile
saline; Humulin R U-100, Eli Lilly). Glucose was determined
using a handheld glucometer (Bayer Contour Next).
NMR body composition
Body composition was determined in the Echo MRI 3-
in-1, time domain nuclear magnetic resonance (TD-NMR)
system. Body weight was measured on a standard labo-
ratory balance before mice were placed in to a clear, cy-
lindrical holder. The tube was gently inserted in to the
boor for an ;2-min measurement. Adiposity (% body fat)
was calculated as ((fat mass/total body weight)  100).
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Plasma lipid measurements
Blood was collected in K2 EDTA (1.0mg) microtainer
tubes (BD) at harvest (non-fasted) and kept at room tem-
perature for at least 30min to prevent clotting and then
centrifuged at 22°C for 15min at 5000 rpm. Plasma was
carefully collected and aliquoted. Plasma was character-
ized on the Beckman Coulter AU680 chemistry analyzer.
Behavioral battery
All the tasks performed by The Jackson Laboratory’s
Mouse Neurobehavioral Facility (MNBF) were previously
validated using control B6 mice. The spontaneous alter-
nation task, a measure of working memory, was con-
ducted as previously described (Sukoff Rizzo et al., 2018).
Briefly, a clear Plexiglas Y-maze was used under ad-
justed, ambient lighting (;50 lux). Subject mice were ac-
climated to the testing room for 1 h before testing. Tested
mice were then placed midway of the start arm (A), facing
the center of the Y for an 8-min test period, and the se-
quence of entries into each arm are recorded via a ceiling
mounted camera integrated with behavioral tracking soft-
ware (Noldus Ethovision). The percentage of spontaneous
alternation was calculated as the number of triads (entries
into each of the three different arms of the maze in a se-
quence of three without returning to a previously visited
arm) relative to the number of alteration opportunities.
For assessment of open field activity, open field arenas
(40  40  40 cm; Omnitech Electronics) were used. A
light fixture mounted ;50 cm above the center of each
arena provided a consistent illumination of ;400–500 lux
in the center of the field. Before the test, mice were accli-
mated to an anteroom outside the testing room for a mini-
mum of 1 h. Subsequently, the tested mice were placed
individually into the center of the arena where the infrared
beams recorded distance traveled (cm), vertical activity,
and perimeter/center time.
For grip strength, subjects were weighed and accli-
mated for at least 1 h before the test. All the grip strength
tests were assessed using the Bioseb grip strength meter
equipped with a grid suited for mice. For forepaw and four
paw grip strength testing, mice were lowered toward the
grid by their tails to allow for visual placing and for the
mouse to grip the grid with their paws. Subjects were
firmly pulled horizontally away from the grid (parallel to
the floor) for six consecutive trials with a brief (,30 s) rest
period on the bench between trials. Trials 1–3 tested only
the forepaw grip, while the following trials 4–6 included all
four paws. The average of the three forepaw trials and the
average of the three four-paw trials were analyzed with
and without normalization for body weight.
Mouse perfusion and tissue preparation
Tissue was collected at 3.5, 12, and 20 months (aged
C3 mice). Mice were anesthetized with a lethal dose of ke-
tamine/xylazine, transcardially perfused with 1 PBS,
and brains carefully dissected and hemisected in the
midsagittal plane. One half was snap-frozen, the other
half immersion fixed in 4% paraformaldehyde (PFA) for
two nights at 4°C. After fixation, half brains were rinsed
in 1  PBS, immersed in 30% sucrose (in 1 PBS) over-
night at 4°C before being frozen in optimal cutting tem-
perature (OCT) compound. Tissue was cryosectioned at
25mm on to glass slides for RNA in situ hybridization and
immunofluorescence.
RNA in situ hybridization
For in situ hybridization, an RNA probe for C1qa (GE
Dharmacon Clone ID 3592169) was synthesized, labeled
with digoxigenin (Dig) and hydrolyzed by standard proce-
dures. Frozen sections were postfixed (4%PFA for 5min),
rinsed twice with 1 PBS and acetylated with 0.25% ace-
tic anhydride for 10min in 0.1 M triethanolamine (TEA).
Sections were then washed in PBS and incubated over-
night at 65°C in hybridization solution [50% formamide,
1 Hybe solution (Sigma-Aldrich), 1mg/ml yeast RNA]
containing 1 g/ml Dig-labeled riboprobe. After hybridiza-
tion, sections were washed by immersion in 0.2 saline-
sodium citrate buffer at 72°C for 1 h. Dig-labeled probes
were detected with an AP-conjugated anti-Dig antibody
(Roche) followed by nitroblue tetrazolium/5-bromo-4-
chloro-3-indolyl phosphate (NBT/BCIP) reaction (Roche).
After in situ hybridization, sections were incubated with
DAPI for nuclei staining and mounted in Aqua PolyMount
(Polysciences) as described previously (Howell et al.,
2011).
Immunofluorescence
For immunostaining with antibodies against vascular
associated proteins, sections were pretreated with pep-
sin as previously described (Soto et al., 2015) with minor
modifications. After pepsin pretreatment, sections were
incubated overnight with the following primary antibod-
ies: goat anti-platelet-derived growth factor receptor b
(PDGFRb ; 1:40, R&D Systems), and rabbit anti-laminin
(LAM; 1:200, Sigma-Aldrich). Sections used for non-vas-
cular associated protein visualization were incubated
overnight in primary antibodies: rabbit anti-Myelin basic
protein (MBP) (1:200, Abcam), or rat anti-(MBP) (1:200,
Abcam), goat anti-IBA1 (1:100, Abcam), or rabbit anti-
IBA1 (1:100, Wako), rat anti-CD68 (1:100, Bio-Rad), rab-
bit anti-C1QA (1:100, Abcam), and goat anti-C3 (1:75,
R&D Systems). After primary antibodies incubation, the
sections were washed 1 PBT (1 PBS1 1% Triton X-
100) and incubated with secondary antibodies for 2 h at
room temperature. After incubation with secondary anti-




For each mouse, four images per brain region (parietal
cortex, corpus callosum and CA1 region of the hippocam-
pus) were generated. Quantifications were performed per
image; therefore, where images contained multiple brain
regions (e.g., parietal cortex, corpus callosum and CA1
region of the hippocampus), these were batched together
(for more details, see Experimental design and statistical
analysis). For quantifying cell number or area, images
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were captured on a Zeiss AxioImager microscope. For
each antibody, all images were captured using identical
parameters for accurate quantification. Where possible,
fluorescent intensity was standardized to samples from
CD-fed mice. However, given the striking difference in in-
tensity between CD-fed and WD-fed mice for MBP, im-
ages were standardized to WD-fed mice.
Quantification in FIJI (ImageJ)
Images for IBA11DAPI1 cells were manually counted
using the cell counter plugin FIJI v1.0. For quantification
of PDGFRb , and laminin, fluorescent area was calculated
using a previously validated in-house Vascular Network
Toolkit (VNT) plugin for FIJI v1.0 (Soto et al., 2015). This
segmentation algorithm was written as an ImageJ macro
for automated processing of images that includes the fol-
lowing steps: Gaussian blur (2 px), “find edges,” variance
(5 px), median (3 px), subtract (s px), multiply (255), invert,
and analyze particles. The analysis of all the images was
automated and blind to the experimenters.
Quantification and visualization in IMARIS
Quantitative analysis of microglia activation (IBA11
cells), microglia phagocytic activity (CD681 phagosomes),
and myelin degradation (MBP) were performed using
IMARIS 8.1 (Bitplane) as previously described (Graham et
al., 2019). Briefly, images captured on the Leica SP5 con-
focal microscope. Z stacks were compiled with 0.2-mm
steps in the z direction with 1024 1024-pixel resolution.
For each antibody, all images were transferred to IMARIS
and rendered using identical parameters and the co-local-
ization tool was used to determine both the surface areas
of MBP, IBA1, and CD68 and the interactions between
surfaces.
Experimental design and statistical analysis
For behavioral analyses, groups of 10–12 mice per sex
per genotype per diet allowed us to detect effects of
.1.15 SE at 80% power as shown previously (Graham et
al., 2019). Changes to vascular structures, white matter
and microglia were identified using sample sizes of at
least 5. Samples sizes are provided in the figure legends
(n, biological replicate and refers to number of mice/sam-
ples used in each experiment). Region of interest was
standardized for all statistical analyses: hippocampus
CA1 (region including stratum radiatum, pyramidal layer
and stratum oriens), cortex (region including posterior
cortex, layers 4–6), corpus callosum (region between CA1
and posterior parietal cortex). Regions determined based
on Allen Brain Atlas.
All data were analyzed using GraphPad Prism software.
For comparisons between two groups, significance was
calculated using unpaired t tests. For multiple compari-
sons, significance was calculated using multi-factorial
analysis of variance (ANOVA) followed by Tukey’s post
hoc tests. ANOVA assumes equal variance and this was
determined before each test using the Brown–Forsythe
test; p values provided are as stated by GraphPad Prism
software and significance was determined with p , 0.05.
SEM was used in all graphs.
Results
Transcriptional profiling demonstrated that WD-in-
duced obese male mice have an increased expression of
complement components, including the central compo-
nents C1qa, C1qb, C1qc, and C3, in the brain when com-
pared with non-obese mice fed a CD (Fig. 1A; Graham et
al., 2019). To determine the location and extent of com-
plement deposition in the brain of obese mice, male mice
were fed either a WD or CD from twomonths of age for
10months. RNA in situ hybridization in 12-month brains
showed a significant increase in the numbers of C1qa1-
expressing cells in the cortex and hippocampus from
WD-fed compared with CD-fed mice (Fig. 1B,C). Also, the
intensity and size of staining for each C1qa1 cell
Figure 1. Complement components are increased in brains of WD-fed obese mice. A, Expression of complement proteins upregu-
lated in brains of WD-fed mice (red boxes). B–D, Increased number of C1qa1 cells in the hippocampus and cortex of WD-fed mice.
Data are presented as mean 6 SEM, n 5, ppp, 0.01 and ppppp, 0.001 by paired t test. Scale bars: 50mm.
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appeared greater in WD-fed compared with CD-fed mice,
features previously suggested to represent activated my-
eloid cells (Davis et al., 2017). C1Q and C3 immunostain-
ing appeared greater in the corpus callosum in WD-fed
compared with CD-fed mice (Fig. 2). Little to no C1Q or
C3 immunostaining was observed in the corpus callosum
of young mice or in brains from mice deficient in C1qa
and C3 (Extended Data Fig. 1). The increase in
Figure 2. C1QA and C3 deposits increase in white matter tracts of WD-fed mice. A, Increased C1QA immunoreactivity in the corpus
callosum of WD-fed compared with CD-fed mice colocalized with IBA11 cells and MBP1 myelin. B, Increased C3 immunoreactivity
in the corpus callosum of WD-fed compared with CD-fed mice colocalized with MBP1 myelin. White dotted lines indicate the
boundary between the CA1 region of the hippocampus and the corpus callosum. Scale bars: 40mm.
Figure 3. WD-induced obesity and metabolic profiles were not altered by C1QA deficiency. A–D, Weight and adiposity increased in
WD-fed mice independent of genotype and sex. E–H, No differences were detected in total cholesterol (E, G) and triglycerides (F,
H) between WD-fed WT and C1qa KO mice. I–L, LDL and HDL plasma levels in male and female WD-fed mice were not changed by
C1QA deficiency. M, N, Fatty acids plasma levels were not altered by C1QA deficiency. Data are presented as mean 6 SEM, n 5,
pp, 0.05, ppp, 0.01, pppp, 0.001, ppppp, 0.0001 by one-way ANOVA with Tukey’s post hoc test. n.s., not significant.
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complement components in WD-fed compared with CD-
fed mice appeared due to changes in microglia as C1Q
and C3 immunoreactivity co-localized with IBA1, a marker
of microglia.
To elucidate the role of complement activation in brains
of obese mice, B6.C1qa/ [C1qa knock-out (KO)] mice
were generated (see Materials and Methods; Extended
Data Fig. 2A). RNA in situ hybridization with C1qa ribop-
robes confirmed the complete absence of C1qa expres-
sion in the brain of B6.C1qa/ mice (Extended Data Fig.
2B,C). Cohorts of 10–12 male and female C1qa KO and
B6 (WT) control mice were established. At two months,
mice were fed either a WD or a CD. At 12 months, mice
were assessed for characteristics of metabolic syndrome
that included weight, glucose and insulin tolerance. WD-
fed C1qa KO male and female mice both gained weight
similarly to their WD-fed WT littermate controls (Fig. 3A,
C). Consistent with higher total weight, the percentage of
adiposity was greater in males and females from both
WD-fed mouse strains when compared with CD-fed mice
(Fig. 3B,D). Lipid profiling of plasma from WD-fed and
CD-fed mice showed that total cholesterol levels in males
and females were increased in both C1qa KO and WT
mice when compared with CD-fed mice (Fig. 3E,G).
Figure 4. C1QA deficiency did not alter glucose or insulin tolerance in obese mice. A–D, No significant changes were detected in
glucose tolerance between genotypes and sex. Only WD-fed male mice showed a moderate impaired glucose tolerance that was
prevented by C1QA deficiency (B). E–H, No changes were observed in the ITT between groups. Data are presented as mean 6
SEM, n 5, pp,0.05 by one-way ANOVA with Tukey’s post hoc test.
Figure 5. C1QA deficiency prevented WD-induced cognitive deficits in male mice. A, B, WD-fed male mice showed a significant im-
pairment in % correct alternation (A), which was not due to reductions in total activity as measured by total arm entries (B).
However, C1qa KO WD-fed male mice showed no significant impairment in % correct alternations when compared with CD-fed
male mice. C, D, No differences were observed in % correct alternations between CD-fed and WD-fed female mice. E, G, Activity
levels in the open field as measured by cumulative distance traveled revealed no differences between groups in both male and fe-
male mice. F, H, Grip strength measurements were not different between groups in both male and female mice. Data are presented
as mean 6 SEM, n8, pp, 0.05 by one-way ANOVA with Tukey’s post hoc test.
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Triglyceride levels were decreased in C1qa KO males and
unchanged in females from WT and C1QA-deficient mice
(Fig. 3F,H). The levels of LDL were only increased in males
by the WD in both mouse strains (Fig. 3I,K), while HDL lev-
els were increased in both females and males from WD-
fed mice (Fig. 3J,L). Changes in the level of fatty acids
were not found in any of the experimental groups (Fig.
3M,N). Obesity is a high risk for insulin resistance, there-
fore glucodynamic responses were evaluated in WD-fed
and CD-fed WT and C1QA-deficient mice. While no
changes in blood glucose levels were found in the basal,
non-fasting state (Fig. 4A,C), only WD-fed WT males pre-
sented a moderate impaired glucose tolerance, that was
prevented by the deficiency of C1QA in the WD-fed C1qa
KO males (Fig. 4B,D). Finally, no differences in insulin lev-
els were observed (Fig. 4E–H). Collectively, these data
show WD-fed C1qa KO and WT mice were obese but not
insulin resistant or diabetic.
Cognitive health was tested in all mice at 12 months
using a previously validated spontaneous alternation Y-
maze task, a measure of working memory (Graham et al.,
2019). Male and female CD-fed mice were able to perform
the task. In contrast, WD-fed male WT mice showed a sig-
nificant impairment in their ability to alternate between the
arms of the Y-maze indicative of a deficit in working mem-
ory (Fig. 5A–D). In contrast, male and female C1qa KO
mice either fed the WD or the CD were able to perform the
task (Fig. 5A–D). No differences in locomotor activity lev-
els (Fig. 5E,G) and grip strength (Fig. 5F,H) were found be-
tween the experimental groups. These data suggest that
although C1QA deficiency did not alter obesity it did pre-
vent deficits in working memory observed in WD-fed male
mice.
The effect of complement activation on cerebrovascular
function in aging, diseased brains or obesity is not well
studied. Cerebrovascular damage occurs in the aging
brain in humans and animal studies (Bell et al., 2010;
Montagne et al., 2015; Soto et al., 2015). Importantly,
pericyte and basement membrane coverage on vessels is
significantly reduced in aged mice and correlates with an
increase in C1qa-expressing myeloid cells (Soto et al.,
2015). Age-dependent cerebrovascular damage is exa-
cerbated by obesity (Tucsek et al., 2014; Graham et al.,
2019). As with aging, cerebrovascular damage correlates
with increased expression of C1qa in myeloid cells (Soto
et al., 2015). To determine the potential for complement
inhibition to prevent cerebrovascular damage in obesity,
we first assessed pericytes number using PDGFRb im-
munoreactivity. The number of PDGFRb1 cells was sig-
nificantly reduced in WD-fed WT obese mice compared
with CD-fed WT mice (Fig. 6A,B). In contrast, there was
no significant difference in the numbers of PDGFRb1
cells in C1qa KO mice fed either the WD or CD. We next
assessed laminin, a major component of the basement
membrane. While there was a significant decrease in the
density of laminin1 capillaries in WD-fed WT obese mice
when compared with CD-fed mice, no significant differ-
ence was found in WD-fed C1qa KO obese mice when
compared with mice fed the CD (Fig. 6A,C). These results
suggest that C1Q plays a role in obesity-induced cerebro-
vascular damage.
High-fat diets, Westernized diets and obesity have
been shown to induce systemic inflammation, including
proinflammatory responses in peripheral tissues and can
lead to neuroinflammation and cognitive decline (Ownby,
2010). In this study (Figs. 1, 2) and our previous studies
(Soto et al., 2015; Graham et al., 2016), IBA11 myeloid
cells appear to produce the majority of C1qa transcript
and C1QA protein in the brains of WD-fed obese mice. As
reported recently by our group, increased phagocytosis
of myelin by microglia is observed in WD-fed obese mice
(Graham et al., 2019). Therefore, to determine whether
Figure 6. C1QA deficiency prevented WD-diet induced cerebrovascular damage. A–C, WD-induced decrease in PDGFRb1 peri-
cytes in WT mice was prevented by C1QA deficiency (A, B). The decrease of laminin1 capillary density caused by WD was pre-
vented by C1QA deficiency (A, C). Representative images are from a region of the parietal cortex (above the CA1 region of the
hippocampus; see Materials and Methods). Data are presented as mean 6 SEM, n 5, pp, 0.05 by one-way ANOVA with Tukey’s
post hoc test. Scale bars: 30mm. n.s., not significant.
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C1QA deficiency prevents obesity-induced phagocytic
activity of microglia and myelin degradation, brain sec-
tions that contained a portion of the CA1 region of the hip-
pocampus, corpus callosum, and cortex from 12-month
WD-fed and CD-fed C1qa KO and WT mice were immu-
nostained for IBA1 (myeloid cells marker), CD68 (lyso-
somes/phagosomes), and MBP (myelin basic protein).
Images were processed and analyzed using IMARIS (with
brain regions batched together; see Materials and
Methods). There were significantly greater IBA11 surfaces
in the WD-fed WT compared with CD-fed WT mice (Fig.
7A–D,E). There were also significantly greater CD681
surfaces in WD-fed WT compared with CD-fed WT mice
(Fig. 7A–D,F), indicative of increased phagocytic activity.
Deficiency of C1QA prevented the increase in both IBA11
and CD681 surfaces in WD-fed C1qa KOmice (Fig. 7E,F).
Phagocytosis of myelin by activated microglia is in-
creased in the presence of complement proteins (DeJong
and Smith, 1997). Therefore, myelin-positive regions in a
portion of the CA1 region of the hippocampus, the corpus
callosum and the parietal cortex were assessed using
MBP, a major constituent of myelin. Images were again
processed and analyzed using IMARIS (see Materials and
Methods). As expected based on our previous study
(Graham et al., 2019), MBP1 surfaces in brain sections
from WD-fed WT mice were significantly decreased when
compared with CD-fed WTmice, particularly in the corpus
callosum (Fig. 8A,B,D). However, no changes in MBP lev-
els were found in brain sections of WD-fed C1qa KO com-
pared with CD-fed WT and C1qa KO mice, indicating that
deficiency of C1QA prevented the obesity-induced degra-
dation of myelin. Next, the interactions of IBA11 cells with
MBP immunostained myelin were assessed. MBP:IBA1
(myelin-myeloid cells) interactions were significantly in-
creased in WD-fed WT mice compared with CD-fed WT
mice (Fig. 8A,B,E). Colocalization of MBP1 surfaces with
both CD681 and IBA11 surfaces were commonly ob-
served in WD-fed WT mice but were not observed in WD-
Figure 7. WD-induced myeloid cell activation was prevented by C1QA deficiency. A, B, The increase in the number of IBA11 (A, B,
E) and CD681 (A, B, F) surfaces in WD-fed WT was prevented by C1QA deficiency. C–D, Representative examples of IBA11CD681
microglia. Microglia from WD-fed WT mice showed the greatest levels of CD68. Representative images for quantification are shown
that contain a portion of the CA1 of the hippocampus, the corpus callosum and the parietal cortex. Data are presented as mean 6
SEM, n 4, ppp,0.01 by one-way ANOVA with Tukey’s post hoc test. Scale bars: 30mm (A, B) and 10mm (C, D).
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fed C1qa KO mice (Fig. 8C). These findings suggest
C1QA deficiency prevented the phagocytosis of myelin by
microglia.
Discussion
The increase in many diet-related and obesity-related
diseases in Western societies, including cardiovascular
disease, type 2 diabetes, and dementias, have been
linked to lifestyle changes. However, little is known about
how these changes contribute to long-term brain health
and increase risk for age-related neurodegenerative dis-
ease such as AD and related dementias (Elias et al., 2005;
Esser et al., 2014). Here, we assessed the effects of glob-
ally ablating C1QA, an initiating factor in the classical
pathway of the complement cascade, using C1qa KO
mice. Central components of the classical pathway of
the complement cascade, including C1Q and C3, were
particularly increased in the corpus callosum of WD-fed
compared with CD-fed mice that also presented cere-
brovascular dysfunction, microglial activation and white
matter degradation. Obesity and high body mass index
have been shown to affect other white matter tracks in
the brain (Bolzenius et al., 2015; Papageorgiou et al.,
2017), but whether complement deposition is present in
other white matter tracts in our model is still to be
determined.
Activation of the complement cascade occurs in the
aging brain and in neurodegenerative diseases (for re-
view, see Hammond et al., 2019). This is the first study to
support a damaging role for C1QA in obesity-induced
cerebrovascular damage and white matter loss. However,
the role of the complement cascade in aging and neuro-
degenerative diseases has been more widely studied.
Figure 8. WD-induced myelin loss was prevented by C1QA deficiency. A–D, C1QA deficiency in WD-fed mice prevented the decline
of MBP1 surfaces. The white arrow (C) indicates an example of CD681 and MBP1 surfaces surrounded by IBA11 surfaces, sug-
gesting engulfment. E, C1QA deficiency prevented the increased microglia-myelin interactions observed in WD-fed WT obese mice.
Representative images for quantification are shown in A, B that contain a portion of the CA1 of the hippocampus, the corpus callos-
um and the parietal cortex. The region of the image within the white boxes in B are shown in high resolution in C. Data are pre-
sented as mean 6 SEM, n 4, pp, 0.05, ppppp, 0.0001 by one-way ANOVA with Tukey post hoc test. M.-M. Col = myelin-
microglia colocalization. Scale bars: 30mm (A, B) and 10mm (C).
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Inhibition of C1QA prevented synapse loss in aging mice
and in mouse models of AD, Parkinson’s disease, and
glaucoma (Hammond et al., 2019). However, although in-
hibition of C3 appeared protective to the aging brain, defi-
ciency of C3 exacerbated some phenotypes in mouse
models of AD and glaucoma (Hammond et al., 2019). In
our study, to assess the role of C1QA in WD-induced obe-
sity, we chose to focus on cerebrovascular and white
matter structures as well as microglia activity based on
findings from two previous studies (Graham et al., 2016,
2019). In the first study, in response to a WD, neuroinflam-
mation was identified as a major consequence of chronic
consumption of a WD. A small but significant loss of neu-
rons in the cortex but not the hippocampus was identified
(Graham et al., 2016). In the second study, transcriptional
profiling supported increased neuroinflammation, as well
as cerebrovascular and white matter changes in response
to a WD (Graham et al., 2019). In this study, C1QA defi-
ciency prevented pericyte loss and the reduction in lami-
nin density observed in C1QA sufficient WT mice fed the
WD. Additional experiments are still required to deter-
mine the degree to which C1QA deficiency impacts
blood brain barrier integrity and function. The effect of
complement deficiency on neuronal numbers as well as
neuronal structures such as synapses and axons in
obese brains is also still to be determined. However, this
study further supports the complex and important role of
the complement cascade in aging, obesity and neurode-
generative diseases.
The pathologies described here as a result of WD-in-
duced obesity, that were prevented by C1QA deficiency,
are similar to those observed in cerebrovascular-rele-
vant dementias, often grouped as vascular contributions
to cognitive impairment and dementia (VCID). The path-
ologies include small vessel disease, neurovascular dys-
function and white matter hyperintensities or diffuse
demyelination (de Leeuw et al., 2001; van Norden et al.,
2011; Alber et al., 2019). The effect of complement acti-
vation on cerebrovascular health in aging, diseased
brains, or obesity is not well studied. Cerebrovascular
dysfunction occurs in the aging brain in humans and ani-
mal studies (Bell et al., 2010; Montagne et al., 2015;
Soto et al., 2015). Importantly, pericyte and basement
membrane coverage on vessels is significantly reduced
in aged mice and correlates with an increase in C1qa-ex-
pressing myeloid cells (Soto et al., 2015). Age-depend-
ent cerebrovascular decline is exacerbated by obesity
(Tucsek et al., 2014; Graham et al., 2019). As with aging,
cerebrovascular decline correlates with increased expres-
sion of C1qa in myeloid cells (Soto et al., 2015). C3 deposi-
tion has been reported on cerebral vessels of AD patients,
suggesting a possible role of complement in cerebrovas-
cular decline (Shi et al., 2019). Furthermore, complement
synthesis is increased in activated microglia preceding
blood brain barrier dysfunction in an inducible rat model of
neurotoxicity, suggesting complement proteins can di-
rectly damage the cerebrovasculature (Lynch et al., 2004).
In fact, it is thought that the cerebrovasculature is partic-
ularly susceptible to complement components as it can
be exposed to these proteins that are produced in the
brain and/or circulating in the blood. In vitro,
complement receptors such as the C3aRs and C5aRs
are expressed in small numbers on endothelial cells and
can induce signaling cascades that are distinct from leu-
kocytes (Schraufstatter et al., 2002; Hernandez et al.,
2017). C1Q can bind endothelial cells directly causing in-
creased expression of adhesions molecules such as in-
tracellular adhesion molecule-1 (ICAM-1) and vascular
cell adhesion molecule-1 (VCAM-1; Storini et al., 2005).
Therefore, our data support targeting members of the
complement cascade as a viable strategy to alleviate
symptoms in chronic brain disorders that include a sig-
nificant cerebrovascular component.
White matter changes that appear to have occurred as
a result of damaging actions by microglia were pre-
vented by C1QA deficiency in obese mice. However, the
initiating factors of these damaging responses are not
clear. Previous studies have shown that microglia play
an important role in the degradation of myelin through
myelin turnover. Phagocytosis of myelin by activated mi-
croglia is increased in the presence of complement pro-
teins (DeJong and Smith, 1997). Interestingly, one study
showed that specifically targeting pericytes was suffi-
cient to induce white matter dysfunction (Montagne et
al., 2018), indicating that pericyte “stress” in response to
chronic consumption of a WD may be an early and im-
portant event in our obese mice. Neurovascular unit
breakdown and cerebral small vessel disease are known
to increase damaging neuroinflammatory responses by
microglia and astrocytes (del Zoppo, 2009; Soto et al.,
2015). Astrocyte reactivity could directly impact myelin
turnover as it can cause a breakdown in astrocyte-oligo-
dendrocyte gap junctions leading to a failure of remyeli-
nation (Sharma et al., 2010; Markoullis et al., 2014). In
addition, astrocyte reactivity may cause a breakdown in
astrocyte-pericyte or astrocyte-endothelial cell interac-
tions leading to cerebrovascular damage (Abbott, 2002;
Zhao et al., 2015). Given the suggested roles in neuronal
dysfunction, cerebrovascular breakdown and white mat-
ter damage, targeting the complement cascade remains
an important area to study for brain disorders that pres-
ent multiple endophenotypes, as is the case for many
dementias.
Global deletion of the C1qa gene prevented cognitive
decline and the pathologic changes to the cerebrovas-
culature and white matter found in the brain of obese
mice. However, it is not clear whether the protection is
due to the lack of C1QA in the brain or systemically.
Assessment of phenotypes relevant to metabolic syn-
drome such as weight, adiposity and blood cholesterol
were not significantly affected by C1Q deficiency (Figs.
3, 4). However, a detailed examination of lipids and me-
tabolites in the blood or the brain (e.g., by lipidomics and
metabolomics) was not performed meaning we cannot
rule out that the protection to brain structures may be
driven by changes to lipid or metabolite species in C1QA
deficient compared C1QA sufficient mice fed the WD.
The C1QA-mediated protection to brain structures may
also be working at the level of changes to systemic in-
flammation. High-fat diets, Westernized diets and obe-
sity have been shown to induce systemic inflammation,
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including proinflammatory responses in peripheral tis-
sues and can lead to neuroinflammation and cognitive
decline (Ownby, 2010). Systemic inflammation has also
been shown to damage the microvasculature of the brain
in aging and dementia (Grammas and Ovase, 2001;
Grammas et al., 2006). However, in this study, obesity-
induced cerebrovascular damage and white matter loss
was prevented by C1QA deficiency without altering the
weight and metabolic profiles of these mice which were
similar to the WD-fed WT mice. These findings suggest
the protection mediated by C1QA deficiency may be due
to inhibition of complement-expressing microglial cells
directly. Although circulating complement components
account for ;4% of blood proteins, in young, aging dis-
eased brains, complement components are also synthe-
sized by multiple cell types, including myeloid cells,
astrocytes, neurons, and endothelial cells (Hammond et
al., 2019). In the aging brain, microglia and astrocytes
are thought to be a major source of complement proteins
(Fonseca et al., 2017). Our data suggest microglia are
the major producers of C1QA (Figs. 1, 2) in obese brains.
Interestingly, previous studies in our laboratory support
infiltration of peripherally-derived myeloid cells (mono-
cytes/macrophages and neutrophils) into the brain dur-
ing aging that is increased in diet-induced obese mice
(Yang et al., 2019) indicating both resident and peripher-
ally-derived cell types might contribute to increased com-
plement proteins in brains of obese mice. Therefore,
although we refer to the IBA11 and C1QA1 cells in the
brain as microglia, we cannot rule out a contribution from
peripherally-derived IBA11 myeloid cells. Conditionally
ablating components of the complement cascade such as
C1Q and C3 in specific cell types will be needed to pre-
cisely determine the source of complement. However,
although more work is required, this study provides further
support for exploring complement inhibition as viable route
to preserve brain health throughout aging.
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